What counts as the normal dose of Wegovy — and how does the schedule work?

The decision most people don't realise they're making: staying at 2.4mg or going higher

When people search for the normal dose of Wegovy, they often expect a single definitive answer. The honest one is: 2.4mg weekly is where most people settle, but the schedule is a ladder, not a fixed destination. The full list of Wegovy doses covers each rung, but in practice the relevant question is whether you reach 2.4mg without problems, or whether your prescriber adjusts the plan based on how your body responds.

Titration matters for a straightforward reason. Semaglutide slows gastric emptying and acts on appetite centres in the brain; starting at the 2.4mg target immediately would almost certainly cause significant nausea for most people. The graduated approach (a minimum of four weeks at each step) lets the gastrointestinal system adapt. Many patients find the early weeks more comfortable than they expected; others need to stay longer at an intermediate dose before moving on. Both are normal. The prescriber decides, not the calendar.

A practical thing worth doing before any dose change: read the current week's entry in your Patient Information Leaflet. It takes under a minute and confirms exactly when the next injection is due, what to do if a dose is missed, and how long the pen can sit outside the fridge. Small details that matter.

What the titration steps actually look like, and what 'normal' means here

The standard Wegovy titration runs: 0.25mg for weeks 1–4, 0.5mg for weeks 5–8, 1.0mg for weeks 9–12, 1.7mg for weeks 13–16, then 2.4mg from week 17 onward as the maintenance dose. The starting dose guidance explains why 0.25mg exists at all, it is purely a tolerability measure, not a therapeutic target.

At 2.4mg, clinical trial data show meaningful weight reduction over time. The STEP 1 trial, published in the New England Journal of Medicine, reported an average weight loss of around 15% over 68 weeks at the 2.4mg maintenance dose alongside lifestyle changes. That figure comes from a specific trial population and clinical context; individual results vary, and the medicine works alongside, not instead of, dietary and activity changes.

For people who do not respond sufficiently at 2.4mg, the MHRA approved a 7.2mg maintenance dose in January 2026. Trial data at that dose reported average weight loss of around 20.7% over 72 weeks. More detail on when and how the higher dose is considered is covered on the Wegovy high-dose page. The 7.2mg dose follows the same graduated titration from 0.25mg, a prescriber would not jump directly to it.

When the 'normal' dose isn't the dose you end up on

Some people do not reach 2.4mg. If side effects at a particular step are persistent rather than transient, a prescriber may recommend staying at a lower dose for longer, or in some cases not increasing further. Nausea, loose stools and reflux are the most commonly reported effects, especially after a step-up; they typically settle within days to a couple of weeks. The guidance on dose increases goes into more detail about how that timing is assessed.

NICE's appraisal of semaglutide for weight management, TA875, notes that if a patient achieves less than 5% weight loss after six months at their maintenance dose, continuing should be reviewed. That review is clinical, not automatic. It is also worth knowing that the NICE recommendation for Wegovy on the NHS specifies use within a specialist weight management service for a maximum of two years, private prescribing timelines differ and are agreed with your prescriber.

People sometimes ask whether the dose of the weekly injection is comparable to normal semaglutide dosing for other conditions. It is not directly comparable: semaglutide dosing varies by licensed indication, and the Wegovy weight-management schedule is specific to that licence. Rybelsus, for instance, is oral semaglutide licensed for type 2 diabetes, its tablet strengths follow a completely different scale and should never be confused with Wegovy doses.

Getting the dose right through a regulated private service

Wegovy is a prescription-only medicine. The dose you use is not a personal choice made at the point of purchase, it is the outcome of a clinical assessment that looks at your BMI, any relevant conditions, current medicines and your response to treatment over time. Every pen dose supplied through a legitimate pharmacy should correspond to a prescriber's instruction, not a default setting.

For context on what private Wegovy treatment costs, the Wegovy price page covers what a complete service includes and where pricing sits in the UK market. At nume, a real prescriber reviews every consultation the same day, not automated software. That review covers eligibility, starting dose and the titration plan. If treatment is approved, dispatch follows that day for orders received before noon, with free next-working-day tracked delivery.

If questions arise during treatment (about whether it is the right moment to step up, or how to handle a missed injection) the support team is available seven days a week, and the treating prescriber can be reached through the aftercare service. The treatment options page is the place to start a free consultation if you want a prescriber to assess which dose pathway suits your situation.